We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BioVendor Group

BioVendor Group is an international group of biotechnology companies (BioVendor LM, BioVendor R&D, TestLine, ViennaLa... read more Featured Products: More products

Download Mobile App




Urine Neutrophil Gelatinase-Associated Lipocalin Predicts Acute Kidney Injury

By LabMedica International staff writers
Posted on 15 Nov 2022
Print article
Image: A Human Lipocalin-2/ neutrophil gelatinase-associated lipocalin (NGAL) sandwich ELISA kit (Photo courtesy of Epitope Diagnostics Inc.)
Image: A Human Lipocalin-2/ neutrophil gelatinase-associated lipocalin (NGAL) sandwich ELISA kit (Photo courtesy of Epitope Diagnostics Inc.)

Despite the increasing heterogeneity of etiology, making a definitive and timely diagnosis of acute kidney injury (AKI) remains challenging. Currently, the diagnosis of AKI is still based on elevated serum creatinine concentration or decreased urinary excretion. However, increased serum creatinine and decreased urine volume usually occur 48 hours after renal injury.

Contrast-associated acute kidney injury (CA-AKI) is an early complication after percutaneous coronary intervention (PCI). Depending on the study subjects, the rate of acute kidney injury can occur from 4.2% to 50%. CA-AKI after PCI is often associated with contrast drugs, hemodynamic instability, old age, pre-existing chronic kidney disease, or a combination of diabetes and hypertension.

Medical Scientists at the Vietnam Military Medical University (Hanoi, Vietnam) included in a study 509 patients with chronic coronary artery disease, indicated for planned percutaneous coronary intervention at two centers. The patients were divided into two groups: group 1, 153 elderly patients ≥70 years old and group 2, 356 patients <70 years old. The team collected fasting morning venous blood plasma to determine concentrations of hs-CRP, hs-TnT, ALT, AST, cholesterol, triglyceride, HDL-C, LDL-C, electrolyte, glucose, urea, and creatinine.

The patient's 24 hour-urine sample was collected on the day before the procedure. After 24 hours, the team measures the urine volume, took 5 mL of urine to determine the neutrophil gelatinase-associated lipocalin (NGAL) level, and then calculated the 24-h urine NGAL concentration. Urine NGAL was measured by the Human Lipocalin-2/NGAL ELISA kit (BioVendor, Brno, Czech Republic) based on the sandwich enzyme immunoassay method. All patients had their glomerular filtration rate (eGFR) calculated based on the MDRD formula.

The investigators reported that the ratio of CA-AKI in group 1 was 23.5% which was higher than that of group 2 (8.7%). Urine NGAL level in group 1 was significantly higher than that of group 2 (31.3 (19.16–55.13) ng/mL versus 19.86 (13.21–29.04) ng/mL. At a cut-off value of 44.43 ng/ml, urinary NGAL had a predictive value for CA-AKI in all patients (AUC = 0.977). Especially at a cut-off value of 44.14 ng/mL, urinary NGAL had a predictive value for CA-AKI in elderly patients (AUC = 0.979).

The authors concluded that the rate of CA-AKI after PCI in elderly patients was 23.5%. Urine NGAL before PCI has a good predictive value for CA-AKI in elderly patients who received planned percutaneous coronary intervention. The study was published on November 10, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
Vietnam Military Medical University
BioVendor

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
HIV Test
Anti-HIV (1/2) Rapid Test Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.